News summary

Digbi Health’s GLP-1 care model claims 18.4% weight loss

Source: Longevity Technology • Published: 18 Nov 2026, 18:35

Summarized by Masters of Longevity from Longevity Technology.

Digbi Health reported 18.4% average weight loss with tirzepatide plus its program.

Digbi Health’s GLP-1 care model claims 18.4% weight loss
Key Takeaways
  • Digbi Health reports 18.4% mean weight loss with program.
  • Reported results compare favorably to published tirzepatide cohorts.
  • These observational comparisons have not established causality yet.
Read the full article at Longevity Technology ↗

Continue exploring

Recommended MoL Picks

MoL PickThe Next Obesity-Drug Race Is About What Weight You LoseRegeneron’s myostatin and activin A antibodies point to a sharper question for the GLP-1 era: not whether people can lose more weight, but whether medicine can preserve the tissue that makes weight loss healthier.MoL PickSemaglutide Extended Lifespan in Mice. What Would Make It a Human Longevity Drug?A new animal study sharpens an important question: when do benefits in a particular disease become evidence for a longer, healthier life?MoL PickApoB: The cholesterol signal LDL can missIn longevity medicine, the useful biomarkers are not always the exotic ones. ApoB is a relatively simple blood test that can sharpen cardiovascular prevention when LDL-C looks reassuring but particle burden remains high.